BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 33277683)

  • 1. NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU.
    Sultova E; Westphalen CB; Jung A; Kumbrink J; Kirchner T; Mayr D; Rudelius M; Ormanns S; Heinemann V; Metzeler KH; Greif PA; Burges A; Trillsch F; Mahner S; Harbeck N; Wuerstlein R
    Arch Gynecol Obstet; 2021 May; 303(5):1331-1345. PubMed ID: 33277683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lessons learned: the first consecutive 1000 patients of the CCCMunich
    Heinrich K; Miller-Phillips L; Ziemann F; Hasselmann K; Rühlmann K; Flach M; Biro D; von Bergwelt-Baildon M; Holch J; Herold T; von Baumgarten L; Greif PA; Jeremias I; Wuerstlein R; Casuscelli J; Spitzweg C; Seidensticker M; Renz B; Corradini S; Baumeister P; Goni E; Tufman A; Jung A; Kumbrink J; Kirchner T; Klauschen F; Metzeler KH; Heinemann V; Westphalen CB
    J Cancer Res Clin Oncol; 2023 May; 149(5):1905-1915. PubMed ID: 35796778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NGS-Guided Precision Oncology in Breast Cancer and Gynecological Tumors-A Retrospective Molecular Tumor Board Analysis.
    Gremke N; Rodepeter FR; Teply-Szymanski J; Griewing S; Boekhoff J; Stroh A; Tarawneh TS; Riera-Knorrenschild J; Balser C; Hattesohl A; Middeke M; Ross P; Litmeyer AS; Romey M; Stiewe T; Wündisch T; Neubauer A; Denkert C; Wagner U; Mack EKM
    Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672643
    [No Abstract]   [Full Text] [Related]  

  • 4. Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.
    Tafe LJ; Gorlov IP; de Abreu FB; Lefferts JA; Liu X; Pettus JR; Marotti JD; Bloch KJ; Memoli VA; Suriawinata AA; Dragnev KH; Fadul CE; Schwartz GN; Morgan CR; Holderness BM; Peterson JD; Tsongalis GJ; Miller TW; Chamberlin MD
    Oncologist; 2015 Sep; 20(9):1011-8. PubMed ID: 26205736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetics and beyond: Precision Medicine Real-World Data for Patients with Cervical, Vaginal or Vulvar Cancer in a Tertiary Cancer Center.
    Kraus FBT; Sultova E; Heinrich K; Jung A; Westphalen CB; Tauber CV; Kumbrink J; Rudelius M; Klauschen F; Greif PA; König A; Chelariu-Raicu A; Czogalla B; Burges A; Mahner S; Wuerstlein R; Trillsch F
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementation of Precision Oncology for Patients with Metastatic Breast Cancer in an Interdisciplinary MTB Setting.
    Sultova E; Westphalen CB; Jung A; Kumbrink J; Kirchner T; Mayr D; Rudelius M; Ormanns S; Heinemann V; Metzeler KH; Greif PA; Hester A; Mahner S; Harbeck N; Wuerstlein R
    Diagnostics (Basel); 2021 Apr; 11(4):. PubMed ID: 33924134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer.
    Hlevnjak M; Schulze M; Elgaafary S; Fremd C; Michel L; Beck K; Pfütze K; Richter D; Wolf S; Horak P; Kreutzfeldt S; Pixberg C; Hutter B; Ishaque N; Hirsch S; Gieldon L; Stenzinger A; Springfeld C; Smetanay K; Seitz J; Mavratzas A; Brors B; Kirsten R; Schuetz F; Fröhling S; Sinn HP; Jäger D; Thewes V; Zapatka M; Lichter P; Schneeweiss A
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34036222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective.
    Weiss L; Heinrich K; Zhang D; Dorman K; Rühlmann K; Hasselmann K; Klauschen F; Kumbrink J; Jung A; Rudelius M; Mock A; Ormanns S; Kunz WG; Roessler D; Beyer G; Corradini S; Heinzerling L; Haas M; von Bergwelt-Baildon M; Boeck S; Heinemann V; Westphalen CB
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8225-8234. PubMed ID: 37062035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich
    Dorman K; Zhang D; Heinrich K; Reeh L; Weiss L; Haas M; Beyer G; Rössler D; Goni E; Renz BW; D'Haese JG; Kunz WG; Seidensticker M; Corradini S; Niyazi M; Ormanns S; Kumbrink J; Jung A; Klauschen F; Werner J; Mayerle J; von Bergwelt-Baildon M; Boeck S; Heinemann V; Westphalen CB
    Target Oncol; 2023 Mar; 18(2):257-267. PubMed ID: 36853374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementing precision oncology for sarcoma patients: the CCC
    Berclaz LM; Burkhard-Meier A; Lange P; Di Gioia D; Schmidt M; Knösel T; Klauschen F; von Bergwelt-Baildon M; Heinemann V; Greif PA; Westphalen CB; Heinrich K; Lindner LH
    J Cancer Res Clin Oncol; 2023 Nov; 149(15):13973-13983. PubMed ID: 37542550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine.
    Charo LM; Eskander RN; Sicklick J; Kim KH; Lim HJ; Okamura R; Lee S; Subramanian R; Schwab R; Shatsky R; Plaxe S; Kato S; Kurzrock R
    JCO Precis Oncol; 2022 Jan; 6():e2000508. PubMed ID: 35005995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses.
    Huang CC; Tsai YF; Liu CY; Chao TC; Lien PJ; Lin YS; Feng CJ; Chiu JH; Hsu CY; Tseng LM
    BMC Cancer; 2021 Feb; 21(1):199. PubMed ID: 33632156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial.
    Trédan O; Wang Q; Pissaloux D; Cassier P; de la Fouchardière A; Fayette J; Desseigne F; Ray-Coquard I; de la Fouchardière C; Frappaz D; Heudel PE; Bonneville-Levard A; Fléchon A; Sarabi M; Guibert P; Bachelot T; Pérol M; You B; Bonnin N; Collard O; Leyronnas C; Attignon V; Baudet C; Sohier E; Villemin JP; Viari A; Boyault S; Lantuejoul S; Paindavoine S; Treillleux I; Rodriguez C; Agrapart V; Corset V; Garin G; Chabaud S; Pérol D; Blay JY;
    Ann Oncol; 2019 May; 30(5):757-765. PubMed ID: 30865223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Retrospective Analysis of Biliary Tract Cancer Patients Presented to the Molecular Tumor Board at the Comprehensive Cancer Center Munich.
    Zhang D; Dorman K; Heinrich K; Weiss L; Boukovala M; Haas M; Greif PA; Ziemann F; Beyer G; Roessler D; Goni E; Renz B; D'Haese JG; Kunz WG; Seidensticker M; Corradini S; Niyazi M; Ormanns S; Kumbrink J; Jung A; Mock A; Rudelius M; Klauschen F; Werner J; Mayerle J; von Bergwelt-Baildon M; Boeck S; Heinemann V; Westphalen CB
    Target Oncol; 2023 Sep; 18(5):767-776. PubMed ID: 37594677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers.
    Rodriguez-Rodriguez L; Hirshfield KM; Rojas V; DiPaola RS; Gibbon D; Hellmann M; Isani S; Leiser A; Riedlinger GM; Wagreich A; Ali SM; Elvin JA; Miller VA; Ganesan S
    Gynecol Oncol; 2016 Apr; 141(1):2-9. PubMed ID: 27016222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Study-An Asian Tertiary Cancer Center Experience.
    Seet AOL; Tan AC; Tan TJ; Ng MCH; Tai DWM; Lam JYC; Tan GS; Gogna A; Too CW; Tan BS; Takano A; Lim A; Lim TH; Lim ST; Dent RA; Ang MK; Yap YS; Tan IBH; Choo SP; Toh CK; Lim EH; Farid M; Skanderup AJ; Iyer NG; Lim WT; Tan EH; Lim TKH; Tan DSW
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting.
    VanderWalde A; Grothey A; Vaena D; Vidal G; ElNaggar A; Bufalino G; Schwartzberg L
    J Pers Med; 2020 Nov; 10(4):. PubMed ID: 33260805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of molecular testing in clinical practice in gynecologic cancers.
    Huang M; Hunter T; Slomovitz B; Schlumbrecht M
    Cancer Med; 2019 May; 8(5):2013-2019. PubMed ID: 30848097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation and utilization of the molecular tumor board to guide precision medicine.
    Harada S; Arend R; Dai Q; Levesque JA; Winokur TS; Guo R; Heslin MJ; Nabell L; Nabors LB; Limdi NA; Roth KA; Partridge EE; Siegal GP; Yang ES
    Oncotarget; 2017 Aug; 8(34):57845-57854. PubMed ID: 28915716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of panel gene sequencing on therapy of advanced cancers of the digestive system: a retrospective, single center study.
    Dreikhausen L; Klupsch A; Wiest I; Xiao Q; Schulte N; Betge J; Boch T; Brochhausen C; Gaiser T; Hofheinz RD; Ebert M; Zhan T
    BMC Cancer; 2024 Apr; 24(1):526. PubMed ID: 38664720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.